ClinConnect ClinConnect Logo
Search / Trial NCT07045987

Exploration and Establishment of an Early Warning System for Futile Reperfusion - A I S

Launched by XIJING HOSPITAL · Jun 23, 2025

Trial Information

Current as of July 06, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Aged ≥18 years 2. Acute ischemic stroke confirmed by clinical and neuroimaging criteria (CT or MRI) 3. Clinical indication for thrombectomy 4. Provision of signed informed consent
  • Exclusion Criteria:
  • 1. Preexisting dementia or severe disability (modified Rankin Scale score ≥3) 2. Cerebral vascular malformations, neoplasms, abscesses, or other significant non-ischemic brain pathologies 3. Life-limiting systemic comorbidities (e.g., end-stage organ failure, metastatic malignancies) with anticipated survival \<6 months 4. Patient or legally authorized representative declined consent 5. Anticipated poor protocol adherence or loss to follow-up

About Xijing Hospital

Xijing Hospital, a prominent medical institution affiliated with the Fourth Military Medical University in Xi'an, China, is dedicated to advancing healthcare through innovative clinical research. Renowned for its comprehensive range of medical services and expertise in various specialties, Xijing Hospital actively sponsors clinical trials aimed at evaluating new therapies, improving patient outcomes, and contributing to scientific knowledge. With a commitment to ethical standards and patient safety, the hospital fosters collaboration among multidisciplinary teams to drive forward the development of effective treatment options that address critical health challenges.

Locations

Xi'an, Shanxi, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported